There was some testing of ABT-450 with interferon, but not enough to form the basis of anything consequential. ABBV essentially put the program on hold until discovering that ABT-450 could form the backbone of an effective all-oral regimen.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”